Kai-Hua Lu
Overview
Explore the profile of Kai-Hua Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ke Z, Chen Y, Yu T, Zhang Q, Xiang Y, Lu K
Cancer Med
. 2024 Dec;
13(23):e70486.
PMID: 39660409
Background: Immune biomarkers for non-small-cell lung cancer (NSCLC) are programmed death ligand 1 (PD-L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate...
2.
Yu S, Yang J, Zhang Q, Yu T, Lu K
Am J Transl Res
. 2024 Jun;
16(5):2082-2102.
PMID: 38883377
Programmed cell death (PCD) plays a pivotal role in tumor initiation and progression. However, the prognostic value and clinical characteristics of PCD-related genes (PRGs) remain unclear. We collected and analyzed...
3.
Sun M, Nie F, Zang C, Wang Y, Hou J, Wei C, et al.
Mol Ther
. 2024 Jun;
32(7):2426.
PMID: 38857596
No abstract available.
4.
Yu S, Yu T, Wang Y, Sun A, Liu J, Lu K
J Transl Med
. 2024 May;
22(1):460.
PMID: 38750462
Background: Chaperonin Containing TCP1 Subunit 6 A (CCT6A) is a prominent protein involved in the folding and stabilization of newly synthesized proteins. However, its roles and underlying mechanisms in lung...
5.
Yu T, Nie F, Zhang Q, Yu S, Zhang M, Wang Q, et al.
Cell Death Dis
. 2024 Jan;
15(1):12.
PMID: 38182561
Lung squamous cell carcinoma (LUSC) is a subtype of lung cancer for which precision therapy is lacking. Chimeric antigen receptor T-cells (CAR-T) have the potential to eliminate cancer cells by...
6.
Yu T, Zhang Q, Yu S, Nie F, Zhang M, Wang Q, et al.
Cell Death Dis
. 2023 Jul;
14(7):475.
PMID: 37500615
The THO complex (THOC) is ubiquitously involved in RNA modification and various THOC proteins have been reported to regulate tumor development. However, the role of THOC3 in lung cancer remains...
7.
Wang Q, Yu T, Ke Z, Wang F, Yin J, Shao Y, et al.
Front Oncol
. 2023 Jul;
13:1172728.
PMID: 37441425
Introduction: Immune checkpoint inhibitors (ICI) have changed the treatment of non-small cell lung cancer (NSCLC). Furthermore, compared with monotherapy, ICI combination therapy had better efficacy and partly different mechanism. Therefore,...
8.
Yu T, Yu S, Lu K
Pathol Oncol Res
. 2022 Oct;
28:1610610.
PMID: 36313898
Solute carrier (SLC) family members are crucial in transporting amino acids across membranes. Amino acids are indispensable for both cancer and immune cells. However, the clinical significance of amino acid...
9.
Yu T, Yu S, Xiang Y, Lu K, Sun M
Front Immunol
. 2022 Jul;
13:936496.
PMID: 35903099
Chimeric antigen receptor (CAR)-T cells have enormous potentials for clinical therapies. The CAR-T therapy has been approved for treating hematological malignancies. However, their application is limited in solid tumors owing...
10.
Li M, Zhou C, Yang J, Lu S, Zheng D, Hu J, et al.
Cancer Biol Ther
. 2019 Apr;
20(8):1097-1104.
PMID: 30990107
Literatures regarding the prevalence and clinical significance of compound EGFR mutations are limited. Until now, none of retrospective or prospective research has focused on compound mutations except case reports. In...